A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase no. 11. Available from: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012 [last accessed 17 Apr 2019].
   Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714–26.
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741–51.
   PubMed Web of Science ®Google Scholar
• Laurenzana A, Margheri F, Biagioni A, et al. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells. EBioMedicine 2019;39:194–206.
   PubMed Web of Science ®Google Scholar
• Ruzzolini J, Peppicelli S, Andreucci E, et al. Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH. Cancer Lett 2017;408:43–54.
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Chang WA, Huang MS, et al. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem 2014;2014:1–8.
   Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett 2015;368:7–13.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv Exp Med Biol 2014;812:19–24.
   PubMed Web of Science ®Google Scholar
• Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014;15:1243–53.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Jiang YC, Sun CK, et al. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep 2016;35:2499–515.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Andreucci E, Ruzzolini J, et al. The acidic microenvironment as a possible niche of dormant tumor cells. Cell Mol Life Sci 2017;74:2761–71.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Bianchini F, Toti A, et al. Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. Cell Cycle 2015;14:3088–100.
   PubMed Web of Science ®Google Scholar
• Kim SY. Cancer energy metabolism: shutting power off cancer factory. Biomol Ther (Seoul) 2018;26:39–44.
   PubMed Web of Science ®Google Scholar
• Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev 2018;54:8–21.
   PubMed Web of Science ®Google Scholar
• Laurenzana A, Chillà A, Luciani C, et al. uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells. Int J Cancer 2017;141:1190–200.
   PubMed Web of Science ®Google Scholar
• Simon JA, van Kuijk A, Yaromina R, et al. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front Oncol 2016;6:69.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites 2017;8:2.
   PubMed Web of Science ®Google Scholar
• Kemura K, Hiramatsu S, Okuda M. Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front Pharm 2017;8:911.
   PubMed Web of Science ®Google Scholar
• Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541–9.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70.
   PubMed Web of Science ®Google Scholar
• Singh S, Lomelino CL, Mboge MY, et al. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules 2018;23:1045.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran C. T Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). Expert Opin Ther Pat 2018;28:729–40.
   PubMed Web of Science ®Google Scholar
• Andreucci E, Ruzzolini J, Peppicelli S, et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem 2019;34:117–23.
   PubMed Web of Science ®Google Scholar
• Damaskos C, Valsami S, Kontos M, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res 2017;37:35–46.
   PubMed Web of Science ®Google Scholar
• Xu W, Parmigiani R, Marks P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541–52.
   PubMed Web of Science ®Google Scholar
• Long J, Zhao J, Yan Z, et al. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40. Int J Cancer 2009;124:1235–44.
   PubMed Web of Science ®Google Scholar
• Expression of HDAC1 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000116478-HDAC1/pathology [last accessed on 10 Jan 2019].
   Google Scholar
• Expression of HDAC3 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000171720-HDAC3/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Expression of HDAC8 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000147099-HDAC8/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Expression of HDAC4 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000068024-HDAC4/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Expression of HDAC5 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000108840-HDAC5/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Expression of HDAC9 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000048052-HDAC9/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Expression of HDAC2 in cancer summary. The Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000196591-HDAC2/pathology [last accessed 10 Jan 2019].
   Google Scholar
• Ahn MY, Lee J, Na YJ, et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 2009;179:169–77.
   PubMed Web of Science ®Google Scholar
• Laurenzana A, Balliu M, Cellai C, et al. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One 2013;8:e58267.
   PubMed Web of Science ®Google Scholar
• Cellai C, Balliu M, Laurenzana A, et al. The new low-toxic histone decetyalse S-(2) induces apoptosis in various acute myeloid leukemia cells. J Cell Mol Med 2012;16:1758–65.
   PubMedGoogle Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, et al., for the Mayo P2C Phase II Consortium. Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94:1375–82.
   PubMed Web of Science ®Google Scholar
• Guandalini L, Cellai C, Laurenzana A, et al. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Bioorg Med Chem Lett 2008;18:5071–4.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247–52.
   PubMed Web of Science ®Google Scholar
• Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci 2013;34:656–66.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387–90.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Nikolaou M, Pavlopoulou A, Georgakilas AG, et al. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 2018;34:309–18.
   Google Scholar
• Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679–92.
   PubMed Web of Science ®Google Scholar
• Chen S-H, Lahav G. Two is better than one; toward a rational design on combinatorial therapy. Curr Opin Struct Biol 2016;41:145–50.
   PubMed Web of Science ®Google Scholar
• Bulusu KC, Guha R, Mason DJ, et al. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov Today 2016;21:225–38.
   PubMed Web of Science ®Google Scholar
• Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659–66.
   PubMed Web of Science ®Google Scholar
• O’Neil J, Benita Y, Feldman I, et al. An unbiased oncology compound screen to identify novel combination strategies. Mol Cancer Ther 2016;15:1155–62.
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802–11.
   PubMed Web of Science ®Google Scholar
• Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med 2017;95:1341–53.
   PubMed Web of Science ®Google Scholar
• Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097–116.
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Kremser M-L, Strohmeier B, et al. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR path-way. J Pathol 2008;216:495–504.
   PubMed Web of Science ®Google Scholar
• Dietrich CS, Greenberg VL, Desimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) protentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 2010;116:126–30.
   PubMed Web of Science ®Google Scholar
• Mrakovcic M, Kleinheinz J, Fröhlich LF. p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death. Int J Mol Sci 2019;20:2415.
   Web of Science ®Google Scholar
• Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, et al. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer 2017;24:156.
   Google Scholar
• Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?. J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
• Di Fiore A, Maresca A, Supuran CT, De Simone G. Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb) 2012;48:8838–40.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–87.
   PubMed Web of Science ®Google Scholar